… In Phase 1, 2, and 3 clinical trials, dapagliflozin has exhibited a safety and tolerability profile
similar to … Dapagliflozin has the potential to be the next new oral agent in the diabetes drug …

… levels following 24 weeks of dapagliflozin treatment. The change in mean HbA1c from
baseline was −0.77 to −0.82% and −0.89% for 5 mg and 10 mg dapagliflozin doses, respectively, …

… is to review the efficacy and safety of dapagliflozin , a novel … dapagliflozin in lowering the
HbA1c in patients with T2DM. It also discusses additional non-glycemic benefits of dapagliflozin …

… Dapagliflozin was the first drug in a class of therapies that took a new approach to glycemic
control in adults with type 2 diabetes (… to the action, efficacy, and clinical use of dapagliflozin. …

… two-thirds of the total weight loss [19]. At week 24, patients receiving add-on dapagliflozin 10
mg … A rapid decline in bodyweight was seen in the first few weeks of dapagliflozin treatment, …

… Dapagliflozin treatment was associated with a reduction in HbA 1c [weighted mean …
Dapagliflozin monotherapy did not lead to hypoglycaemia [relative risk (RR): 1.44; 95% CI: 0. 86, 2.41…

… dapagliflozin, we outline the phase II clinical trials and international phase III studies that
investigated the utility of dapagliflozin. … of dapagliflozin in the management of type 2 diabetes by …

… to determine the pharmacodynamic effects of dapagliflozin, as measured by urinary glucose
… daily (QD) dapagliflozin treatment or placebo for 12 weeks from two phase 2 studies were …

… All English-language reports evaluating dapagliflozin were … prevalence of type 2 diabetes,
suboptimal management of the … , novel therapeutic strategies are needed for its treatment. …

… Data Synthesis: We evaluated 9 clinical trials with dapagliflozin as … dapagliflozin to be
noninferior to metformin in treatment naïve patients for reduction in A1C. Additionally, dapagliflozin …